AWM
CKPT

Apollon Wealth Management’s Checkpoint Therapeutics CKPT Stock Holding History

Apollon Wealth Management’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,534
Closed -$36.9K – 1223
2024
Q4 		$36.9K Hold
11,534
– – ﹤0.01% 1180
2024
Q3 		$25.8K Hold
11,534
– – ﹤0.01% 1119
2024
Q2 		$24.8K Hold
11,534
– – ﹤0.01% 1087
2024
Q1 		$23.6K Buy
+11,534
New +$23K ﹤0.01% 1103
2023
Q4 		– Sell
-13,900
Closed -$23.6K – 1075
2023
Q3 		$23.6K Sell
13,900
-30,529
-69% -$69.4K ﹤0.01% 896
2023
Q2 		$110K Buy
44,429
+10,050
+29% +$27.5K 0.01% 898
2023
Q1 		$77.4K Buy
34,379
+8,021
+30% +$40.3K ﹤0.01% 832
2022
Q4 		$135K Buy
26,358
+13,423
+104% +$96.7K 0.01% 801
2022
Q3 		$135K Buy
12,935
+3,125
+32% +$37.2K 0.01% 747
2022
Q2 		$101K Buy
9,810
+2,236
+30% +$29.3K 0.01% 714
2022
Q1 		$134K Buy
+7,574
New +$163K 0.01% 714

Other funds holding CKPT

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GLF
Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Apollon Wealth Management's CKPT Position: Q1 2025 in Review

Apollon Wealth Management sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 11,534 shares — an estimated $36.9K sold.

Apollon Wealth Management first reported a position in CKPT in Q1 2022 and held it in 11 quarters. The position peaked at $135K in Q3 2022. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

  • Apollon Wealth Management reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Apollon Wealth Management sold 11,534 Checkpoint Therapeutics shares in Q1 2025, an estimated $36.9K.
  • Apollon Wealth Management first reported a position in Checkpoint Therapeutics in Q1 2022 and held it in 11 quarters.
  • Apollon Wealth Management's Checkpoint Therapeutics position peaked at $135K in Q3 2022.
  • 84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Apollon Wealth Management's 13F filing for Q1 2025, filed 2 May 2025.